Randomized Clinical Outcome Trials in Hypertension.
作者信息
Mancia Giuseppe, Kjeldsen Sverre E
机构信息
University of Milan-Bicocca, Milan, Italy (G.M.).
University of Oslo, Institute of Clinical Medicine, Medical Faculty, Oslo, Norway (S.E.K.).
出版信息
Hypertension. 2024 Jan;81(1):17-23. doi: 10.1161/HYPERTENSIONAHA.123.21725. Epub 2023 Oct 5.
Abstract
摘要
相似文献
1
Randomized Clinical Outcome Trials in Hypertension.高血压的随机临床疗效试验
Hypertension. 2024 Jan;81(1):17-23. doi: 10.1161/HYPERTENSIONAHA.123.21725. Epub 2023 Oct 5.
2
The blood pressure measurement--revisited.血压测量——再探讨
Am Heart J. 2006 Sep;152(3):417-9. doi: 10.1016/j.ahj.2006.03.016.
3
Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials.临床试验中降压对复合心血管终点的影响。
J Hypertens. 2010 Jul;28(7):1356-65. doi: 10.1097/HJH.0b013e328338e2bb.
4
Added benefits of nifedipine (Adalat GITS) beyond lowering blood pressure.硝苯地平控释片（拜新同）除降低血压外的额外益处。
Cardiovasc J S Afr. 2004 Jul-Aug;15(4):198-9.
5
The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.盎格鲁-斯堪的纳维亚心脏结局试验——降压组
J Clin Pharm Ther. 2006 Aug;31(4):299-307. doi: 10.1111/j.1365-2710.2006.00760.x.
6
We All Benefit From Antihypertensive Drug Therapy Regardless of Sex, Though Cautions Remain.无论性别如何，我们都能从降压药物治疗中获益，不过仍需谨慎。
Hypertension. 2023 Nov;80(11):2303-2305. doi: 10.1161/HYPERTENSIONAHA.123.21774. Epub 2023 Oct 18.
7
Who is fooling us?谁在愚弄我们？
Lancet. 2002 Sep 14;360(9336):873-4. doi: 10.1016/S0140-6736(02)09974-9.
8
Hypertension (Blood Pressure) and Lifetime Risk of Target Organ Damage.高血压（血压）与靶器官损伤的终身风险。
Curr Hypertens Rep. 2020 Sep 2;22(10):75. doi: 10.1007/s11906-020-01086-6.
9
Largest meta-analysis to date suggests that patients at risk for cardiovascular disease events derive benefit from antihypertensive therapy regardless of baseline blood pressure and to reduce vascular events, lowering blood pressure is more important than choice of antihypertensive drug class.迄今为止最大规模的荟萃分析表明，有心血管疾病事件风险的患者无论基线血压如何，均可从抗高血压治疗中获益，且为降低血管事件风险，降低血压比选择抗高血压药物类别更为重要。
J Clin Hypertens (Greenwich). 2009 Dec;11(12):743-5. doi: 10.1111/j.1751-7176.2009.00207.x.
10
Treatment of Hypertension Induced Target Organ Damage.高血压所致靶器官损害的治疗
Curr Pharm Des. 2018;24(37):4377. doi: 10.2174/138161282437190227103636.
引用本文的文献
1
[Cardiovascular preventive recommendations. PAPPS 2024 thematic updates].[心血管疾病预防建议。PAPPS 2024主题更新]
Aten Primaria. 2024 Nov;56 Suppl 1(Suppl 1):103123. doi: 10.1016/j.aprim.2024.103123.
本文引用的文献
1
Target blood pressure in isolated systolic hypertension: a meta-analysis of randomized outcome trials.单纯收缩期高血压的目标血压：随机结局试验的荟萃分析
J Hypertens. 2023 Dec 1;41(12):2113-2114. doi: 10.1097/HJH.0000000000003476. Epub 2023 Nov 2.
2
Effect of antihypertensive treatment in isolated systolic hypertension (ISH) - systematic review and meta-analysis of randomised controlled trials.孤立性收缩期高血压（ISH）降压治疗效果的系统评价和随机对照试验荟萃分析。
Blood Press. 2023 Dec;32(1):2226757. doi: 10.1080/08037051.2023.2226757.
3
Evidence in favour of ambulatory blood pressure grows but gaps in knowledge remain.支持动态血压监测的证据越来越多，但仍存在知识空白。
Lancet. 2023 Jun 17;401(10393):2014-2015. doi: 10.1016/S0140-6736(23)00442-7. Epub 2023 May 5.
4
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes.2型糖尿病患者与非2型糖尿病患者的血压降低及主要心血管事件
Lancet Diabetes Endocrinol. 2022 Dec;10(12):840. doi: 10.1016/S2213-8587(22)00312-6.
5
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.英国成人高血压患者中常规降压药物晚间与晨间给药的心血管结局（TIME 研究）：一项前瞻性、随机、开放标签、盲终点临床试验。
Lancet. 2022 Oct 22;400(10361):1417-1425. doi: 10.1016/S0140-6736(22)01786-X. Epub 2022 Oct 11.
6
Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective.高血压研究中源数据验证的缺失：透视HYGIA项目
Hypertension. 2021 Aug;78(2):555-558. doi: 10.1161/HYPERTENSIONAHA.121.17356. Epub 2021 Jul 7.
7
Antihypertensive Treatment in Elderly Frail Patients: Evidence From a Large Italian Database.老年虚弱患者的降压治疗：来自大型意大利数据库的证据。
Hypertension. 2020 Aug;76(2):442-449. doi: 10.1161/HYPERTENSIONAHA.120.14683. Epub 2020 Jun 8.
8
Does Intensive Glucose Control Cancel Out Benefits of Systolic Blood Pressure Target <120 mm Hg in Patients With Diabetes Mellitus Participating in ACCORD?强化血糖控制是否会抵消糖尿病患者参与ACCORD试验中收缩压目标<120 mmHg的益处？
Hypertension. 2018 Aug;72(2):291-293. doi: 10.1161/HYPERTENSIONAHA.118.11455. Epub 2018 Jul 2.
9
Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach.2 型糖尿病的血压目标。积极治疗的证据是否确凿。
Diabetologia. 2018 Mar;61(3):517-525. doi: 10.1007/s00125-017-4537-3. Epub 2018 Jan 25.
10
Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials.降压治疗对结局发生率的影响。12. 血压正常高值和正常血压个体的治疗效果：随机试验的概述与荟萃分析。
J Hypertens. 2017 Nov;35(11):2150-2160. doi: 10.1097/HJH.0000000000001547.
Zotero 插件